Royalty Pharma plc · RPRX · Next earnings

Royalty Pharma plc reports Wednesday, Nov 4, 2026

RPRX reports before market open with consensus EPS at $1.18 and revenue at $884.8M. Last quarter: Royalty Pharma Raises Guidance as Receipts and Co-Funding Expand

Reports Before market open0 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $1.18 Calendar consensus
Consensus revenue $884.8M Calendar consensus
Report date Nov 4, 2026 Wednesday, date estimated
Session Before market open 0 days away

Where RPRX left off: FY2026 Q3

Full report

Royalty Pharma Raises Guidance as Receipts and Co-Funding Expand

EPS surprise — Reported — vs $1.18
Revenue surprise — Reported — vs $884.8M
Stock move +1.4% Event window
Subsequent drift 0.0% Up to 20 sessions

Full-year guidance was raised for the third consecutive quarter. The supplied analysis does not specify the revised range or the size of the increase.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Clinical and regulatory setbacks, including the reported Phase III failure of pelacarsen and pending decisions for other assets.
  • Competition and fast-follower dynamics could affect the commercial potential of newly acquired therapies.
  • Acquisition pace, deal structure and capital deployment discipline remain important given the uncertain outcomes of development-stage assets.

Questions analysts left open

  • Whether competition limits the prospects of newly acquired therapies.
  • Potential financial impact from trial failures, including pelacarsen or olpasiran.
  • Whether deployment pace and deal protections adequately balance growth with downside risk.

Ask FN2 about RPRX next report

Transcript, numbers and history already loaded
What should I watch for in RPRX's next earnings report?How did RPRX guide last quarter, and is consensus above or below that?Give me the bull and bear case going into RPRX earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the RPRX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent RPRX quarters

All RPRX earnings
+1.4%FY2026 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.